CBIO biotech catalysts & pipeline

CRESCENT BIOPHARMA INC · Data as of 2026-10-25

Upcoming catalysts

sacituzumab tirumotecan ("sac-TMT") — Initial data

Jul 2026–Aug 2027

Additionally, Kelun recently initiated a Phase 2 clinical study in China of its trophoblast cell-surface antigen 2 (TROP2)-directed ADC sacituzumab tirumotecan ("sac-TMT") in combination with CR-001 to evaluate the safety, tolerability, and efficacy of patients with non-small cell lung cancer ("NSCLC"), with initial data anticipated in mid-2027 (second or third quarter).

Source filing

CR-001 (SKB118) — Initial data

Q1 2027

The Company is on track to report initial monotherapy data from ASCEND in the first quarter of 2027, including preliminary antitumor response as measured by overall response rate ("ORR") from a first-line non-small cell lung cancer ("NSCLC") cohort of up to 12 patients and the safety, tolerability, pharmacokinetic and pharmacodynamic data from more than 125 treatment-naive and previously-treated patients across multiple solid tumor types.

Source filing

CR-003 (SKB105) — Clinical data readout

Q1 2027

A Phase 1/2 trial of CR-003 (SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the first quarter of 2027.

Source filing

CR-001 (SKB118) — Initial data

in mid-2027

A Phase 2 trial of CR-001 (SKB118) and sac-TMT in participants with locally advanced or metastatic NSCLC is ongoing with initial data expected in mid-2027;

Source filing

CR-002 — Initial data

H2 2027

Initial data are expected in the second half of 2027.

Source filing

ASCEND — Conference presentation

Oct 23–Oct 27

Trial in progress posters on the ASCEND study design will be presented during the European Society for Medical Oncology (ESMO) 2026 Congress being held October 23-27, 2026 in Madrid, Spain and at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting being held November 4-8, 2026 in Phoenix, Arizona.

Source filing

ASCEND — Conference presentation

Nov 4–Nov 8

Trial in progress posters on the ASCEND study design will be presented during the European Society for Medical Oncology (ESMO) 2026 Congress being held October 23-27, 2026 in Madrid, Spain and at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting being held November 4-8, 2026 in Phoenix, Arizona.

Source filing

Explore the free biotech catalyst calendar